Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement. - PubMed - NCBI

Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement. - PubMed - NCBI

Immunol Res. 2017 Feb 21. doi: 10.1007/s12026-017-8907-1. [Epub ahead of print]

Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement.

Modell V1, Quinn J1, Ginsberg G1, Gladue R1, Orange J2, Modell F3.

Author information

Abstract

This study seeks to generate analytic insights into risk management and probability of an identifiable primary immunodeficiency defect. The Jeffrey Modell Centers Network database, Jeffrey Modell Foundation's 10 Warning Signs, the 4 Stages of Testing Algorithm, physician-reported clinical outcomes, programs of physician education and public awareness, the SPIRIT® Analyzer, and newborn screening, taken together, generates P values of less than 0.05%. This indicates that the data results do not occur by chance, and that there is a better than 95% probability that the data are valid. The objectives are to improve patients' quality of life, while generating significant reduction of costs. The advances of the world's experts aligned with these JMF programs can generate analytic insights as to risk management and probability of an identifiable primary immunodeficiency defect. This strategy reduces the uncertainties related to primary immunodeficiency risks, as we can screen, test, identify, and treat undiagnosed patients. We can also address regional differences and prevalence, age, gender, treatment modalities, and sites of care, as well as economic benefits. These tools support high net benefits, substantial financial savings, and significant reduction of costs. All stakeholders, including patients, clinicians, pharmaceutical companies, third party payers, and government healthcare agencies, must address the earliest possible precise diagnosis, appropriate intervention and treatment, as well as stringent control of healthcare costs through risk assessment and outcome measurement. An affected patient is entitled to nothing less, and stakeholders are responsible to utilize tools currently available. Implementation offers a significant challenge to the entire primary immunodeficiency community.

KEYWORDS:

Diagnosis; Immunology; Jeffrey Modell Centers Network (JMCN); Jeffrey Modell Foundation (JMF); Modeling; Outcome measurement; Primary immunodeficiencies (PI); Risk management; Treatment

PMID:

 

28224361

 

DOI:

 

10.1007/s12026-017-8907-1

[PubMed - as supplied by publisher]

Last Posted: Mar 03, 2017

---

• Modeling strategy to identify patients with primary immunodeficiency utilizing risk management and outcome measurement.  
  Modell Vicki et al. Immunologic research 2017 Feb
• Comprehensive genetic testing for primary immunodeficiency disorders in a tertiary hospital: 10-year experience in Auckland, New Zealand.  
  Woon See-Tarn et al. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2016 1265
• Newborn Screening for Severe Primary Immunodeficiency Diseases in Sweden-a 2-Year Pilot TREC and KREC Screening Study.  
  Barbaro Michela et al. Journal of clinical immunology 2016 Nov
• Diagnostics of Primary Immunodeficiencies through Next-Generation Sequencing.  
  Gallo Vera et al. Frontiers in immunology 2016 7466
• Overview of 15-year severe combined immunodeficiency in the Netherlands: towards newborn blood spot screening.  
  de Pagter Anne P J et al. European journal of pediatrics 2015 Sep 174(9) 1183-8
• Guidelines for Screening, Early Diagnosis and Management of Severe Combined Immunodeficiency (SCID) in India.  
  Madkaikar Manisha et al. Indian journal of pediatrics 2016 Feb
• Unbiased targeted next-generation sequencing molecular approach for primary immunodeficiency diseases.  
  Al-Mousa Hamoud et al. The Journal of allergy and clinical immunology 2016 Feb
• The effects of prenatal genetic analysis on fetuses born to carrier mothers with primary immunodeficiency diseases.  
  Lee Wen-I et al. Annals of medicine 2016 Feb 1-8
• Parental Views on Expanded Newborn Screening Using Whole-Genome Sequencing.  
  Joseph Galen et al. Pediatrics 2016 Jan 137 Suppl 1S36-46
• Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015.  
  Picard Capucine et al. Journal of clinical immunology 2015 Oct
• Genomics will redraw the rare disease map: The "Rarity Catch-22",  
  CVID, Primary Immune and Rare Disease Blog, September 19, 2015
• Screening for long-term poliovirus excretion among children with primary immunodeficiency disorders: preparation for the polio posteradication era in Bangladesh.  
  Sazzad Hossain M S et al. J. Infect. Dis. 2014 Nov 1. 210 Suppl 1S373-9
• Vaccine-associated varicella and rubella infections in severe combined immunodeficiency with isolated CD4 lymphocytopenia and mutations in IL7R detected by tandem whole exome sequencing and chromosomal microarray.  
  Bayer D K et al. Clin. Exp. Immunol. 2014 Dec 178(3) 459-69
• Long-term evaluation of a historical cohort of Iranian common variable immunodeficiency patients.  
  Aghamohammadi Asghar et al. Expert Rev Clin Immunol 2014 Oct 10(10) 1405-17
• The Swiss National Registry for Primary Immunodeficiencies: Report on the first 6 years' activity 2008-2014.  
  Marschall Karin et al. Clin. Exp. Immunol. 2015 Jun 1.
• DNA Counseling In The Age of Genomics,  
  by Yoni Maisel, CVID, Primary Immune and Rare Disease Blog, May 26

more